Haleon is the new Consumer Healthcare company, independent of GSK (GlaxoSmithKline). With a remarkable portfolio of globally renowned brands such as Sensodyne, Voltaren, Panadol and Centrum and annual sales of around £ 10 billion, the company is gearing up for a premium listing on the London Stock Exchange. Headquartered in Weybridge, UK, the new name will be found in more than 100 countries where GSK Consumer Healthcare operates. The separation of the two companies will be managed by transferring at least 80% of the shares held by GSK to the shareholders of the new company.
Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum. Its brands are trusted by healthcare professionals, customers worldwide to improve the health and wellbeing of individuals and their communities. Demand from the £150 billion consumer healthcare sector is strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle-class, and unmet consumer needs. The business is therefore well-positioned to deliver human health impact and to sustainably grow ahead of the market in the years to come.
“Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare. We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February.”, said Brian McNamara, Chief Executive Officer Designate, Haleon.
The name was also announced in advance of GSK hosting a Consumer Healthcare Capital Markets Day for investors and analysts on Monday 28 February, to provide details on the overall strategy, capabilities and operations of Haleon, including detailed financial information and growth ambitions of the business. For prospective investors, Haleon will offer attractive organic sales growth, operating margin expansion and consistent high cash generation.
“Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health. Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders.”, said Emma Walmsley, Chief Executive Officer, GSK.
The new name was announced as part of a global celebration for all the people working in GSK Consumer Healthcare earlier today. Employees from around the world had the opportunity to engage with the new name and brand identity which seeks to bring to life the company’s purpose and growth ambitions.